Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2 & PRN473 reduces venous thrombosis formation in mice.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Both G protein–coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice2022 · 32 citations
2. 2Low-dose Btk inhibitors selectively block platelet activation by CLEC-22020 · 62 citations
3. 3A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers2017 · 103 citations
4. 4Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)2022 · 82 citations
5. 5Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI2018 · 74 citations